Search

Your search keyword '"Abada, Paolo B."' showing total 2 results
Start Over Author "Abada, Paolo B." Journal british journal of cancer
2 results on '"Abada, Paolo B."'

1. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study

Author

Chau, Ian, Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Poon, Ronnie, Pastorelli, Davide, Blanc, Jean-Frédéric, Kudo, Masatoshi, Pfiffer, Tulio, Hatano, Etsuro, Chung, Hyun Cheol, Kopeckova, Katerina, Phelip, Jean-Marc, Brandi, Giovanni, Ohkawa, Shinichi, Li, Chung-Pin, Okusaka, Takuji, Hsu, Yanzhi, Abada, Paolo B., and Zhu, Andrew X.

Published
2018
Full Text
View/download PDF

2. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study

Author

Paolo Abada, Baek Yeol Ryoo, Takuji Okusaka, Jean-Marc Phelip, Etsuro Hatano, Chia Jui Yen, Shinichi Ohkawa, Ronnie T.P. Poon, Tulio Eduardo Flesch Pfiffer, Davide Pastorelli, Jean-Frédéric Blanc, Masatoshi Kudo, Hyun Cheol Chung, Andrew X. Zhu, Ian Chau, Chung Pin Li, Yanzhi Hsu, Joon Oh Park, Katerina Kopeckova, Giovanni Brandi, Chau, Ian, Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Poon, Ronnie, Pastorelli, Davide, Blanc, Jean-Frédéric, Kudo, Masatoshi, Pfiffer, Tulio, Hatano, Etsuro, Chung, Hyun Cheol, Kopeckova, Katerina, Phelip, Jean-Marc, Brandi, Giovanni, Ohkawa, Shinichi, Li, Chung-Pin, Okusaka, Takuji, Hsu, Yanzhi, Abada, Paolo B., and Zhu, Andrew X.

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Carcinoma, Hepatocellular, Kaplan-Meier Estimate, Antibodies, Monoclonal, Humanized, Placebo, Gastroenterology, Disease-Free Survival, Article, Ramucirumab, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, medicine, Carcinoma, Humans, neoplasms, Aged, business.industry, Liver Neoplasms, digestive, oral, and skin physiology, Antibodies, Monoclonal, Middle Aged, medicine.disease, digestive system diseases, Radiography, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, embryonic structures, Monoclonal, Female, 030211 gastroenterology & hepatology, alpha-Fetoproteins, Alpha-fetoprotein, business
Abstract

Background Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH. Methods Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed. Results Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to AFP progression (HR 0.621; P P P P = 0.0002). AFP response was higher with ramucirumab compared with placebo (P P Conclusions Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results